Is Kerendia (finerenone) appropriate for a patient with frequent urinary tract infections?

Kerendia is Generally Appropriate for Patients with Frequent UTIs

Kerendia (finerenone) can be used in patients with frequent urinary tract infections, as there is no contraindication or significant safety concern linking finerenone to UTI risk or complications. The decision to use Kerendia should be based on the patient's underlying indication (CKD with type 2 diabetes or heart failure), renal function, and potassium levels—not on UTI history.

Key Clinical Considerations

No Direct UTI-Related Contraindication

The FDA label for Kerendia does not list UTIs as a contraindication, warning, or precaution 1. In clinical trials involving over 6,500 patients with CKD and type 2 diabetes, urinary tract infections were reported in only 4% of participants—a rate that does not suggest finerenone increases UTI risk 2. This is notably different from SGLT2 inhibitors, which are associated with genital mycotic infections.

Standard Indications Must Be Met

Kerendia should only be prescribed if the patient meets appropriate criteria:

For CKD with Type 2 Diabetes:

• eGFR >25 mL/min/1.73 m² 3
• Albuminuria >30 mg/g despite maximum tolerated RAS inhibitor 3
• Serum potassium ≤5.0 mEq/L at initiation 1

For Heart Failure (LVEF ≥40%):

• eGFR ≥25 mL/min/1.73 m² recommended 1
• Normal serum potassium 1

Critical Monitoring Requirements

The primary safety concerns with Kerendia are hyperkalemia (14% incidence) and worsening renal function (particularly in heart failure patients), not UTIs 1:

• Check potassium and eGFR before initiation
• Recheck potassium at 1 month, then every 4 months 3
• Hold if potassium >5.5 mEq/L 3
• More frequent monitoring if patient is on other potassium-sparing medications

UTI Management Considerations

If the patient has frequent UTIs requiring antibiotics:

• Drug interactions: Monitor for moderate CYP3A4 inhibitors (some antibiotics like clarithromycin or erythromycin). These increase finerenone exposure and may require more frequent potassium monitoring 1
• Avoid strong CYP3A4 inhibitors (contraindicated) 1
• Fluoroquinolones and beta-lactams commonly used for UTIs do not significantly interact with finerenone

Real-World Safety Data

The FINE-REAL study of 1,916 patients in routine clinical practice showed UTIs occurred in only 4% of patients on finerenone, with excellent overall tolerability (85% remained on therapy for up to 1 year) 2. Hyperkalemia led to discontinuation in only 1% and hospitalization in 0.3% 2.

Clinical Algorithm

1. Confirm appropriate indication (CKD with T2D or heart failure with preserved EF)
2. Check baseline labs: potassium ≤5.0 mEq/L and eGFR >25 mL/min/1.73 m²
3. Review concomitant medications for CYP3A4 interactions
4. Initiate at appropriate dose based on eGFR (10 mg if eGFR 25-59,20 mg if ≥60) 3, 1
5. Monitor potassium at 1 month, then every 4 months
6. Manage UTIs as clinically indicated—finerenone does not need to be held or adjusted for UTI treatment unless strong CYP3A4 inhibitor antibiotics are required

Common Pitfalls to Avoid

• Do not withhold Kerendia solely due to UTI history—there is no mechanistic or clinical evidence linking the two
• Do not confuse with SGLT2 inhibitors, which do increase genitourinary infections 4
• Do not forget to check for drug interactions if prescribing antibiotics that are CYP3A4 inhibitors 1
• Do not initiate if potassium >5.0 mEq/L regardless of UTI status 1